News >

Lenvatinib Approved in Europe for Frontline HCC

Jason M. Broderick @jasoncology
Published: Thursday, Aug 23, 2018

Gary Hendler

Gary Hendler

The European Commission has approved lenvatinib (Lenvima) as a first-line treatment for adult patients with advanced or unresectable hepatocellular carcinoma (HCC).

The most common grade 3/4 TRAEs with lenvatinib and sorafenib, respectively, were hypertension (23% vs 14%), decreased weight (8% vs 3%), increased blood bilirubin (7% vs 5%), proteinuria (6% vs 2%), decreased platelet count (5% vs 3%), elevated aspartate aminotransferase (5% vs 8%), decreased appetite (5% vs 1%), diarrhea (4% vs 4%), and palmar-plantar erythrodysesthesia (3% vs 11%).
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial [published online February 9, 2018]. Lancet. doi:10.1016/S0140-6736(18)30207-1.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Oncology Consultations®: Discussing the Nurse's Role in Treating and Managing Advanced Pancreatic AdenocarcinomaSep 28, 20191.5
Publication Bottom Border
Border Publication